Liyang Diao, PhD

Seres Therapeutics
Cambridge, Massachusetts, United States

Seres Therapeutics (Employee)

Presentation(s):

• LB15 - SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics

  Saturday, October 2, 2021
  1:15 PM - 3:00 PM EDT